GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lavipharm SA (ATH:LAVI) » Definitions » Short-Term Debt

Lavipharm (ATH:LAVI) Short-Term Debt : €8.04 Mil (As of Jun. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Lavipharm Short-Term Debt?

Lavipharm's Short-Term Debt for the quarter that ended in Jun. 2024 was €8.04 Mil.

Lavipharm's quarterly Short-Term Debt declined from Jun. 2023 (€20.20 Mil) to Dec. 2023 (€7.99 Mil) but then increased from Dec. 2023 (€7.99 Mil) to Jun. 2024 (€8.04 Mil).

Lavipharm's annual Short-Term Debt increased from Dec. 2021 (€21.29 Mil) to Dec. 2022 (€21.61 Mil) but then declined from Dec. 2022 (€21.61 Mil) to Dec. 2023 (€7.99 Mil).


Lavipharm Short-Term Debt Historical Data

The historical data trend for Lavipharm's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lavipharm Short-Term Debt Chart

Lavipharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial 2.31 3.15 21.29 21.61 7.99

Lavipharm Semi-Annual Data
Dec17 Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 4.02 21.61 20.20 7.99 8.04

Lavipharm Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Lavipharm Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Lavipharm's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Lavipharm Business Description

Traded in Other Exchanges
Address
Agias Marinas Street, PO Box 59, Peania Attica, GRC, 19002
Lavipharm SA develops, manufactures, markets and distributes pharmaceutical, cosmetic and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumer' needs for health and wellbeing. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, General Medicine, Self- Treatment and Dermocosmetic care.

Lavipharm Headlines

No Headlines